OTCMKTS:SEOVF Sernova Biotherapeutics (SEOVF) Stock Price, News & Analysis $0.13 +0.01 (+4.24%) As of 01:43 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Sernova Biotherapeutics Stock (OTCMKTS:SEOVF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SEOVF alerts:Sign Up Key Stats Today's Range$0.12▼$0.1350-Day Range$0.10▼$0.1452-Week Range$0.09▼$0.17Volume5,166 shsAverage Volume29,650 shsMarket Capitalization$50.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes. In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration. Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.AI Generated. May Contain Errors. Read More Receive SEOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SEOVF Stock News HeadlinesSernova Biotherapeutics: Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to ...March 4, 2026 | finanznachrichten.deSernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical EffortsNovember 13, 2025 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 5 at 1:00 AM | Banyan Hill Publishing (Ad)Sernova Biotherapeutics Announces Collaboration with Eledon ...July 11, 2025 | morningstar.comMSernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 DiabetesJuly 9, 2025 | globenewswire.comSernova Biotherapeutics Taps CEO to Be Interim ChairJune 2, 2025 | marketwatch.comSernova Appoints Jonathan Rigby as Interim ChairJune 2, 2025 | globenewswire.comChair of Sernova Biotherapeutics ResignsMay 25, 2025 | globenewswire.comSee More Headlines SEOVF Stock Analysis - Frequently Asked Questions How have SEOVF shares performed this year? Sernova Biotherapeutics' stock was trading at $0.0943 at the beginning of the year. Since then, SEOVF stock has increased by 40.9% and is now trading at $0.1329. How were Sernova Biotherapeutics' earnings last quarter? Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) posted its quarterly earnings data on Thursday, March, 19th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.00. How do I buy shares of Sernova Biotherapeutics? Shares of SEOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/19/2026Today5/05/2026Next Earnings (Estimated)6/11/2026Fiscal Year End10/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:SEOVF CIK1491434 Webwww.sernova.com Phone(519) 858-5184Fax519-858-5184EmployeesN/AYear Founded2006Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.24 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-761.41% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-2.66Miscellaneous Outstanding Shares377,642,000Free FloatN/AMarket Cap$50.19 million OptionableNot Optionable Beta0.86 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:SEOVF) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Biotherapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sernova Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.